POLG2 sirna

POLG2 siRNA (Human)

Cat. Num. AAA8205990

• Gene Names: POLG2; HP55; POLB; PEOA4; POLGB; MTPOLB; POLG-BETA
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: POLG2; POLG2 siRNA (Human); MTPOLB; DNA polymerase subunit gamma-2 mitochondrial; DNA polymerase gamma accessory 55 kDa subunit; p55; Mitochondrial DNA polymerase accessory subunit; MtPolB; PolG-beta; POLG2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: POLG2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 485

• Applicable Applications for POLG2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human POLG2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for POLG2 sirna

siRNA to inhibit POLG2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 70887790
• NCBI GeneID: 11232
• NCBI Accession #: NP_009146.2
• NCBI GenBank Nucleotide #: NM_007215.3
• UniProt Accession #: Q9UHN1; O00419; Q0IJ81; Q96GW2; Q9UK35; Q9UK94
• Molecular Weight: 54,911 Da
• NCBI Official Full Name: DNA polymerase subunit gamma-2, mitochondrial
• NCBI Official Synonym Full Names: polymerase (DNA directed), gamma 2, accessory subunit
• NCBI Official Symbol: POLG2
• NCBI Official Synonym Symbols: HP55; POLB; PEOA4; POLGB; MTPOLB; POLG-BETA
• NCBI Protein Information: DNA polymerase subunit gamma-2, mitochondrial
• UniProt Protein Name: DNA polymerase subunit gamma-2, mitochondrial
• Protein Family: DNA polymerase
• UniProt Gene Name: POLG2
• UniProt Synonym Gene Names: MTPOLB; p55
• UniProt Entry Name: DPOG2_HUMAN

NCBI Description

This gene encodes the processivity subunit of the mitochondrial DNA polymerase gamma. The encoded protein forms a heterotrimer containing one catalytic subunit and two processivity subunits. This protein enhances DNA binding and promotes processive DNA synthesis. Mutations in this gene result in autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions.[provided by RefSeq, Sep 2009]

Uniprot Description

POLG2: Mitochondrial polymerase processivity subunit. Stimulates the polymerase and exonuclease activities, and increases the processivity of the enzyme. Binds to ss-DNA. Defects in POLG2 are the cause of progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 4 (PEOA4). Progressive external ophthalmoplegia is characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged- red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

Protein type: Mitochondrial; DNA repair, damage; DNA replication; Transferase; EC 2.7.7.7

Chromosomal Location of Human Ortholog: 17q

Cellular Component: mitochondrial matrix

Molecular Function: identical protein binding; protein binding; DNA binding; DNA-directed DNA polymerase activity

Biological Process: mitochondrion organization and biogenesis; organelle organization and biogenesis; mitochondrial DNA replication; DNA repair; DNA-dependent DNA replication; DNA replication

Disease: Progressive External Ophthalmoplegia With Mitochondrial Dna Deletions, Autosomal Dominant, 4